News | Endovascular Aortic Repair | November 11, 2019

Nexus Arch Branch Stent Graft System Shows Positive Mid-term Results

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch.  #VIVA19 #VIVA2019

The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch. 


November 7, 2019 — The Endospan Ltd. Nexus aortic arch stent graft is a CE mark–approved, off-the-shelf system for endovascular treatment of pathologies extending or involving the aortic arch. Two-year results from a prospective multicenter premarket study including 25 patients (mean age, 73 years) treated with Nexus were presented at the 2019 Vascular Interventional Advances (VIVA) annual meeting.

Mid-term results at a mean 25-month follow-up are stable without any material failure or stent graft issues, said presenter Daniel Clair, M.D., chair of the Department of Surgery at Palmetto Health-USC Medical Group and senior medical director for Surgical Services at Prisma Health–Midlands. However, he said more experience and longer follow-up are necessary to confirm these promising mid-term results.

Nexus is a modular stent graft introduced via a 20 French delivery system with double flushing ports, which allows efficient de-airing. The main module is deployed over an axillofemoral guidewire to extend from the brachiocephalic trunk to the descending aorta and is combined with a pre-curved ascending module that conforms to the ascending aorta.

All patients had aneurysm size >55 mm and were considered high risk for conventional open arch surgery by a multidisciplinary team. Indications for treatment were aneurysm (15 [60%] patients) or dissection (10 [40%] patients), including seven patients previously treated surgically for type A dissection. Thirteen (52%) patients had prior thoracic aortic surgery. Supra-aortic bypasses were performed prior to Nexus implantation.

Technical success was achieved for all intended Nexus introductions and deployments (100%). At 30 days, two (8%) patients died from cardiac causes and two (8%) patients showed nondisabling stroke, which resolved completely within 30 days. During a mean follow-up of 25 months, there was one additional procedure-related mortality from stroke, and one patient was converted to open surgery following retrograde type A dissection. During follow-up, aneurysm size decreased or remained stable in 96% of the patients, with no aneurysm-related deaths.

The Nexus system is the first European CE mark–approved branched stent graft for the aortic arch. Design features that assist in minimizing manipulations may explain the high technical success, low rate of neurologic complications, and durability, allowing safe endovascular repair.

Find information on all the VIVA 2019 Late-breaking Clinical Trials


Related Content

News | Cardiovascular Clinical Studies

March 13, 2023 — BioCardia, Inc., developer of cellular and cell-derived therapeutics for the treatment of ...

Home March 13, 2023
Home
News | Cardiovascular Clinical Studies

March 8, 2023 — A unique community-based partnership, the African American Heart Study, will be conducted to measure the ...

Home March 08, 2023
Home
News | Cardiovascular Clinical Studies

March 6, 2023 — A multifaceted intervention to improve prescribing practices increased the likelihood that patients with ...

Home March 06, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — Providing medications for chronic diseases—for example, cholesterol-lowering, blood pressure and ...

Home March 05, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — The number of deaths and disabling strokes among patients at low surgical risk who were treated with ...

Home March 05, 2023
Home
News | Cardiovascular Clinical Studies

March 5, 2023 — In the largest randomized trial conducted to compare minimally invasive and conventional cardiac ...

Home March 05, 2023
Home
News | Cardiovascular Clinical Studies

February 20, 2023 — Esperion announced that the landmark Cholesterol Lowering via Bempedoic acid, an ACL-Inhibiting ...

Home February 20, 2023
Home
News | Cardiovascular Clinical Studies

February 16, 2023 — Traffic noise may play an essential role in the development and deterioration of ischemic heart ...

Home February 16, 2023
Home
News | Cardiovascular Clinical Studies

February 8, 2023 — Life Molecular Imaging (LMI) announced that the first patient has been imaged with [18F]florbetaben ...

Home February 08, 2023
Home
News | Cardiovascular Clinical Studies

January 26, 2023 — A newly-released study extends the understanding of how acquired mutations in blood cells act as a ...

Home January 26, 2023
Home
Subscribe Now